Delving into the Latest Updates on Cytomegalovirus Immune Globulin(pH4)(Shandong Taibang Biological Products) with Synapse

Overview

Basic Info

Drug Type

Immunoglobulin

Synonyms-

Target-

Mechanism

Immunomodulators

Therapeutic Areas

Infectious DiseasesOther Diseases

Active Indication

Cytomegalovirus viremia

Inactive Indication-

Originator Organization

Shandong Taibang Biological Products Co. Ltd.

Active Organization

Shandong Taibang Biological Products Co. Ltd.

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

A preemptive treatment strategy was adopted to observe and evaluate the therapeutic efficacy of intravenous cytomegalovirus human immunoglobulin (PH4) combined with intravenous ganciclovir in the treatment of CMV viremia after allogeneic hematopoietic stem cell transplantation, and to explore the dose to provide a basis for phase III clinical trials.

Start Date29 Nov 2019

Sponsor / Collaborator

Shandong Taibang Biological Products Co. Ltd.

100 Clinical Results associated with Cytomegalovirus Immune Globulin(pH4)(Shandong Taibang Biological Products)

Login to view more data

100 Translational Medicine associated with Cytomegalovirus Immune Globulin(pH4)(Shandong Taibang Biological Products)

Login to view more data

100 Patents (Medical) associated with Cytomegalovirus Immune Globulin(pH4)(Shandong Taibang Biological Products)

Login to view more data

100 Deals associated with Cytomegalovirus Immune Globulin(pH4)(Shandong Taibang Biological Products)

Login to view more data